communication [at] (Communication)

Innovative technology for biosensors and nanoparticles

photo : David Arraez
Biosensors and nanoparticles are widely used to develop new drugs, optimize patient treatment and to rapidly diagnose disease. They are often used to specifically identify biomarkers for life threatening diseases such as cancer and auto-immune pathologies.

Many biomarkers are complex molecules present in very low concentrations in human samples (tissue, blood, saliva and so forth).

The “GLISS” project arose from a problem that the team of Claude Nogues and Malcolm Buckle had been working on for a number of years: namely, how to reduce non-specific interactions between biological macromolecules and surfaces used in label free biosensors, whilst at the same time optimising the orientation, distribution and availability of molecules immobilised on a surface so as to increase the sensitivity of the biosensors and optimise detection sensitivity.

Gliss : from the project to the start-up

The team discovered an elegant solution -GLISS, which when applied clinically opened up the possibility of early diagnostics thus providing an enormous aide to the medical profession. With the support of the ENS Paris-Saclay we applied for a maturation program that was pre-selected by the SATT Paris-Saclay for a co-construction phase, with the aim to transfer our product to industry and to create a start-up company.

The resulting 18 months finance and assistance allowed us to complete the team by the recruitment of two engineers working in synergy on different aspects of the project. Simultaneously, our project was selected by the Challenge + program at the HEC which involved 10 months of an intensive course covering major aspects involved in the creation of a start-up. This program was crowned with success since our project “GLISS” won first place in the FORUM Challenge +.

The adventure continues with the programmed creation of the start-up in early 2019 and its installation within the ENS Paris-Saclay.